A comparison of drug treatments to prevent a recurrence of melanoma following surgery suggests the newer drug, Opdivo, prevented recurrences to a greater degree than the standard treatment, Yervoy, according to findings presented at the European Society for Medical Oncology annual meeting and published in The New England Journal of Medicine online. About 71% of patients taking Opdivo were recurrence-free after one year, while 61% of those taking Yervoy did not experience a recurrence.
Post-surgery melanoma drug Opdivo shows promise in trial
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.